EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype

Frank C Sciurba, Gerard J Criner, Stephanie A Christenson, Fernando J Martinez, Alberto Papi iD, Nicolas Roche, Jean Bourbeau, Stephanie Korn, Mona Bafadhel iD, MeiLan K Han, Stefanie Kolterer, Karen Miller und 6 weitere

New England Journal of Medicine · 2025-05 · 392 (17) · 1710-1720

DOI: 10.1056/nejmoa2413181 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, 2025-05. Verfasst von Frank C Sciurba und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Pittsburgh, Pittsburgh. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Eosinophilia, Interleukin-5, Pulmonary Disease, Chronic Obstructive. Die Arbeit wurde bisher 187-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: GlaxoSmithKline, GSK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Mepolizumab is a humanized monoclonal antibody that targets interleukin-5, a cytokine that plays a central role in eosinophilic inflammation, which is present in 20 to 40% of patients with chronic obstructive pulmonary disease (COPD). METHODS: In a phase 3, double-blind, randomized, placebo-controlled trial, patients with COPD, a history of exacerbations, and a blood eosinophil count of at least 300 cells per microliter who were receiving triple inhaled therapy were assigned, in a 1:1 ratio, to receive mepolizumab (at a dose of 100 mg) or placebo subcutaneously every 4 weeks for 52 to 104 weeks. The primary end point was the annualized rate of moderate or severe exacerbations. Secondary end points, tested hierarchically to control for multiplicity, were moderate or severe exacerbation as assessed in a time-to-first-event analysis, measures of health-related quality of life and symptoms, and the annualized rate of exacerbations leading to an emergency department visit, hospitalization, or both. RESULTS: Of the 804 patients who underwent randomization, 403 were assigned to receive mepolizumab and 401 to receive placebo. The annualized rate of moderate or severe exacerbations was significantly lower with mepolizumab than with placebo (0.80 vs. 1.01 events per year; rate ratio, 0.79; 95% confidence interval [CI], 0.66 to 0.94; P = 0.01). The time to the first moderate or severe exacerbation was longer with mepolizumab than with placebo (Kaplan-Meier median time to the first moderate or severe exacerbation, 419 vs. 321 days; hazard ratio, 0.77; 95% CI, 0.64 to 0.93; P = 0.009). Between-group differences in measures of health-related quality of life and symptoms were not significant; thus, no statistical inferences regarding subsequent secondary end points in the statistical testing hierarchy were made. The incidence of adverse events was similar in the mepolizumab and placebo groups. CONCLUSIONS: Treatment with mepolizumab led to a lower annualized rate of moderate or severe exacerbations when added to background triple inhaled therapy among patients with COPD and an eosinophilic phenotype. (Funded by GSK; MATINEE ClinicalTrials.gov number, NCT04133909.).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedEosinophiliaInterleukin-5Pulmonary Disease, Chronic ObstructiveAgedFemaleHumansMaleMiddle AgedAdministration, InhalationDisease ProgressionDouble-Blind MethodDrug Therapy, CombinationEosinophilsInjections, SubcutaneousPhenotypeQuality of LifeSeverity of Illness IndexTreatment Outcome

Substanzen

Antibodies, Monoclonal, HumanizedInterleukin-5mepolizumab

Autor:innen und Institutionen

  • Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Pittsburgh, Pittsburgh.
  • Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine, Temple University, Philadelphia.
  • Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, University of California, San Francisco, San Francisco.
  • University of Massachusetts Chan Medical School, Worcester.
  • Department of Translational Medicine, Respiratory Medicine Section, University of Ferrara, Ferrara, Italy.
  • Service de Pneumologie, Assistance Publique-Hôpitaux de Paris Centre-Université Paris Cité, Hôpital et Institut Cochin, Paris.

ORCID-Profile: Alberto Papi, Mona Bafadhel

Förderung

  • GlaxoSmithKline
  • GSK

Zitieren

APA

Sciurba, F. C., Criner, G. J., Christenson, S. A., Martinez, F. J., Papi, A., Roche, N., Bourbeau, J., Korn, S., Bafadhel, M., Han, M. K., Kolterer, S., Miller, K., Mouneimne, D., Fletcher, J., Mayer, B., Min, J., Pavord, I. D., & MATINEE Study Investigators (2025). Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype. New England Journal of Medicine, 392(17), 1710-1720. https://doi.org/10.1056/nejmoa2413181

Vancouver

Sciurba FC, Criner GJ, Christenson SA, Martinez FJ, Papi A, Roche N, et al. Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype. New England Journal of Medicine. 2025;392(17):1710-1720. doi:10.1056/nejmoa2413181

BibTeX
@article{Sciurba2025,
  author = {Sciurba, Frank C and Criner, Gerard J and Christenson, Stephanie A and Martinez, Fernando J and Papi, Alberto and Roche, Nicolas and Bourbeau, Jean and Korn, Stephanie and Bafadhel, Mona and Han, MeiLan K and Kolterer, Stefanie and Miller, Karen and Mouneimne, Dalal and Fletcher, Joanne and Mayer, Bhabita and Min, Jeff and Pavord, Ian D and MATINEE Study Investigators, MATINEE Study Investigators},
  title = {Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {17},
  pages = {1710--1720},
  doi = {10.1056/nejmoa2413181}
}
Kostenlos starten →